P Pharming Group NV
P
Cerrado
1.425 1.21
Resumen
Variación precio
24h
Mínimo
1.419
Máximo
1.425
Ingresos | -7.4M 5.3M |
|---|---|
Ventas | 10M 107M |
BPA | 0.01 |
Margen de beneficios | 4.977 |
Empleados | 407 |
EBITDA | -21M 2.7M |
Próximas Ganancias | 30 jul 2026 |
|---|
Capitalización Mercado | 60M 1B |
|---|---|
Apertura anterior | 0.22 |
Cierre anterior | 1.425 |
Pharming Group NV Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Pharming Group NV previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
